JPWO2019178085A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019178085A5 JPWO2019178085A5 JP2020549002A JP2020549002A JPWO2019178085A5 JP WO2019178085 A5 JPWO2019178085 A5 JP WO2019178085A5 JP 2020549002 A JP2020549002 A JP 2020549002A JP 2020549002 A JP2020549002 A JP 2020549002A JP WO2019178085 A5 JPWO2019178085 A5 JP WO2019178085A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- nucleic acid
- cells
- amino acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023114641A JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643139P | 2018-03-14 | 2018-03-14 | |
| US62/643,139 | 2018-03-14 | ||
| PCT/US2019/021833 WO2019178085A1 (en) | 2018-03-14 | 2019-03-12 | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114641A Division JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518111A JP2021518111A (ja) | 2021-08-02 |
| JPWO2019178085A5 true JPWO2019178085A5 (https=) | 2022-03-18 |
| JP2021518111A5 JP2021518111A5 (https=) | 2022-03-18 |
| JP7314161B2 JP7314161B2 (ja) | 2023-07-25 |
Family
ID=67907266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549002A Active JP7314161B2 (ja) | 2018-03-14 | 2019-03-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
| JP2023114641A Active JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114641A Active JP7696958B2 (ja) | 2018-03-14 | 2023-07-12 | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12606603B2 (https=) |
| EP (2) | EP4491718A3 (https=) |
| JP (2) | JP7314161B2 (https=) |
| KR (2) | KR20260021083A (https=) |
| CN (1) | CN112088165A (https=) |
| AU (2) | AU2019234580B2 (https=) |
| BR (1) | BR112020018534A2 (https=) |
| CA (1) | CA3093791A1 (https=) |
| EA (1) | EA202091984A1 (https=) |
| IL (1) | IL277268A (https=) |
| MX (2) | MX2020009464A (https=) |
| SG (1) | SG11202008926RA (https=) |
| WO (1) | WO2019178085A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019178078A1 (en) | 2018-03-14 | 2019-09-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy |
| CN119654345A (zh) * | 2022-08-25 | 2025-03-18 | 南京传奇生物科技有限公司 | 靶向白介素13受体亚基α2的嵌合抗原受体及其使用方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090257994A1 (en) * | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| EP2220117A2 (en) | 2007-11-30 | 2010-08-25 | Kalobios Pharmaceuticals, Inc. | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| DK2496698T3 (en) * | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| CN104936621A (zh) | 2012-11-07 | 2015-09-23 | 辉瑞公司 | 抗IL-13受体α2抗体和抗体-药物缀合物 |
| JP6345688B2 (ja) | 2012-12-05 | 2018-06-20 | ソラ・バイオサイエンシズ・エルエルシー | タンパク質発現増強ポリペプチド |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP3783098A1 (en) * | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| CN107002084B (zh) * | 2014-09-19 | 2021-09-10 | 希望之城公司 | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 |
| JP7264592B2 (ja) | 2015-01-26 | 2023-04-25 | ザ ユニバーシティー オブ シカゴ | ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用 |
| EP3324984A4 (en) | 2015-07-21 | 2019-03-27 | City of Hope | T-LYMPHOCYTES FOR THE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS |
| JP6905163B2 (ja) * | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
| ES2879700T3 (es) * | 2016-02-05 | 2021-11-22 | Hope City | Administración de células T genomanipuladas para el tratamiento de cánceres en el sistema nervioso central |
| WO2017172981A2 (en) | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| MA45779A (fr) * | 2016-07-29 | 2019-06-05 | Juno Therapeutics Inc | Polypeptides immunomdulateurs et compositions et procédés associés |
| JP2019530440A (ja) * | 2016-09-02 | 2019-10-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物 |
| WO2018156711A1 (en) | 2017-02-22 | 2018-08-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Il13ra2-binding chimeric antigen receptors |
| WO2019178078A1 (en) | 2018-03-14 | 2019-09-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy |
-
2019
- 2019-03-12 SG SG11202008926RA patent/SG11202008926RA/en unknown
- 2019-03-12 BR BR112020018534-5A patent/BR112020018534A2/pt not_active Application Discontinuation
- 2019-03-12 WO PCT/US2019/021833 patent/WO2019178085A1/en not_active Ceased
- 2019-03-12 KR KR1020267001996A patent/KR20260021083A/ko active Pending
- 2019-03-12 KR KR1020207028968A patent/KR102917671B1/ko active Active
- 2019-03-12 EA EA202091984A patent/EA202091984A1/ru unknown
- 2019-03-12 EP EP24214241.2A patent/EP4491718A3/en active Pending
- 2019-03-12 JP JP2020549002A patent/JP7314161B2/ja active Active
- 2019-03-12 US US16/979,475 patent/US12606603B2/en active Active
- 2019-03-12 EP EP19767433.6A patent/EP3765487A4/en not_active Withdrawn
- 2019-03-12 AU AU2019234580A patent/AU2019234580B2/en active Active
- 2019-03-12 CA CA3093791A patent/CA3093791A1/en active Pending
- 2019-03-12 MX MX2020009464A patent/MX2020009464A/es unknown
- 2019-03-12 CN CN201980030021.9A patent/CN112088165A/zh active Pending
-
2020
- 2020-09-10 MX MX2025010440A patent/MX2025010440A/es unknown
- 2020-09-10 IL IL277268A patent/IL277268A/en unknown
-
2023
- 2023-07-12 JP JP2023114641A patent/JP7696958B2/ja active Active
-
2024
- 2024-04-24 AU AU2024202681A patent/AU2024202681A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518108A5 (https=) | ||
| JP7745616B2 (ja) | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 | |
| US20200181228A1 (en) | Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| JP7198670B2 (ja) | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 | |
| CA3108126A1 (en) | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof | |
| JPWO2019178078A5 (https=) | ||
| AU2025220769A1 (en) | Improving immune cell function | |
| JP7696958B2 (ja) | ゼータカインにより指向性を付与したＩＬ－１３受容体α２標的Ｔ細胞免疫療法 | |
| JP2021518111A5 (https=) | ||
| JPWO2019178085A5 (https=) | ||
| EP4382119A1 (en) | A kit for use in the treatment of hematological cancer | |
| WO2024121297A1 (en) | A kit for use in the treatment of hematological cancer | |
| JP2023529443A (ja) | 抗ｃｄ１７１キメラ抗原受容体 | |
| CN120758457A (zh) | 改造的免疫细胞、靶向Mettl13基因的gRNA和应用 |